DS-7011a + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Systemic Lupus Erythematosus
Conditions
Systemic Lupus Erythematosus
Trial Timeline
Feb 2, 2022 → Mar 22, 2023
NCT ID
NCT05203692About DS-7011a + Placebo
DS-7011a + Placebo is a phase 1 stage product being developed by Daiichi Sankyo for Systemic Lupus Erythematosus. The current trial status is completed. This product is registered under clinical trial identifier NCT05203692. Target conditions include Systemic Lupus Erythematosus.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05638802 | Phase 1/2 | Completed |
| NCT05203692 | Phase 1 | Completed |
Competing Products
20 competing products in Systemic Lupus Erythematosus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tabalumab Auto-Injector + Tabalumab Prefilled Syringe | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 2 | 52 |
| MRA(Tocilizumab) + placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| DS-7011a + Placebo | Daiichi Sankyo | Phase 1/2 | 41 |
| Bocidelpar + Placebo | Astellas Pharma | Phase 1 | 33 |
| Parenteral micafungin application + Other parenteral antifungal drugs | Astellas Pharma | Pre-clinical | 23 |
| Micafungin | Astellas Pharma | Phase 2 | 52 |
| E6742 | Eisai | Phase 1/2 | 41 |
| KHK4827 | Kyowa Kirin | Phase 1 | 33 |
| KHK4827 + Placebo | Kyowa Kirin | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Cyclophosphamide | Eli Lilly | Approved | 85 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of Care | Eli Lilly | Phase 3 | 77 |
| LY3361237 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY2127399 + Placebo | Eli Lilly | Phase 3 | 77 |
| LY3361237 + Placebo | Eli Lilly | Phase 1 | 33 |
| LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks | Eli Lilly | Phase 3 | 77 |